Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluorouracil Implants in Early Stage Hepatocellular Carcinoma
NCT01055743Phase 2Unknown
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Aug 2009
- Primary completion
- Aug 2014
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fluorouracil in hepatocellular carcinoma (HCC), sponsored by Simcere Pharmaceutical Group. Primary endpoint: Disease-Free Survival at 3 years. Status: unknown.
02
Drugs
fluorouracil
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01055743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01055743.